STAT July 8, 2024
Eli Lilly said Monday it will acquire Morphic Holding, a biotech developing a treatment for inflammatory bowel disease.
Lilly will pay about $3.2 billion to buy the Waltham, Mass.-based company. That translates to $57 per share, a premium of roughly 79% from Morphic’s Friday closing price.
Morphic’s lead candidate, MORF-057, is...